PI-2620

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Alzheimer DiseaseParkinson's Disease

91 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

1

Leqembi

Eisai

Approved

12

Avelox

Bayer

Approved

—3

Avandia

Jazz Pharmaceuticals

Approved

—4

Estrace

Novo Nordisk

Approved

—5

Aleve

Jazz Pharmaceuticals

Approved

—6

Epidiolex

Jazz Pharmaceuticals

Approved

—7

Rifadin

Sanofi

Approved

—8

Cialis

Eli Lilly

Approved

—9

Farxiga

AstraZeneca

Approved

—10

Keppra

UCB

Approved

—Show 39 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cognition1 trial

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Completed·Roche·Phase 1·NCT04566003·40 enrolled

Brain Injury1 trial

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

Terminated·LLife Molecular Imaging GmbH·Phase 1·NCT05337774·18 enrolled

Cognitive impairment1 trial

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

Completed·JJae Seung Kim·Phase 2·NCT03903211·84 enrolled

Imaging1 trial

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

Completed·—·Phase 1·NCT03510572·20 enrolled

Alzheimer disease1 trial

An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)

Recruiting·LLife Molecular Imaging GmbH·Phase 3·NCT05641688·200 enrolled

Details

Drug Info

Related News